— Third Quarter Revenues of $152.7 Million and
Non-GAAP Diluted Loss Per Share of $0.18 —
— Commercial Launch of ARISTADA™ Underway
Following FDA Approval for the Treatment of Schizophrenia on Oct.
5, 2015 —
— ALKS 3831 for Schizophrenia and ALKS 8700 for
Multiple Sclerosis to Commence Registration Studies Before Year-End
—
Alkermes plc (NASDAQ: ALKS) today reported financial results for
the third quarter of 2015.
“Earlier this month, the FDA approved ARISTADA™ as the first
long-acting atypical antipsychotic for the treatment of
schizophrenia with both once-monthly and six-week dosing. Our
nationwide commercial launch is underway and we are delighted to
bring this important new treatment option to patients and the
treatment community,” said Richard Pops, Chief Executive Officer of
Alkermes. “Alkermes has a number of important milestones ahead that
will drive the growth of the company. Based on our recent
discussions with the FDA, we have determined the design of the
pivotal programs for both ALKS 3831 in schizophrenia and ALKS 8700
in multiple sclerosis and expect to initiate both before year-end.
The pivotal program for ALKS 5461 in major depressive disorder is
advancing rapidly, and we expect data from the first core efficacy
study in the first quarter of 2016.”
“We are pleased by our solid financial performance during the
third quarter and are on track with our financial expectations for
the remainder of 2015. The approval of ARISTADA further strengthens
our commercial portfolio and represents a major financial
opportunity for Alkermes,” commented James Frates, Chief Financial
Officer of Alkermes. “Heading into 2016, we are well-positioned to
invest in our development plans for our late-stage pipeline, the
launch of ARISTADA and drive the growth of VIVITROL®.”
Quarter Ended Sept. 30, 2015
Highlights
- Total revenues for the quarter were
$152.7 million compared to $160.0 million for the same period in
the prior year, or $143.2 million excluding $16.8 million of
revenues from the products associated with the Gainesville
manufacturing facility that was divested in April 2015.
- Net loss according to generally
accepted accounting principles in the U.S. (GAAP) was $81.0
million, or a basic and diluted GAAP loss per share of $0.54, for
the quarter. This compared to GAAP net loss of $40.0 million, or a
basic and diluted GAAP loss per share of $0.27, for the same period
in the prior year, or $34.5 million, or a basic and diluted loss
per share of $0.24, excluding $5.5 million of GAAP net income
related to the Gainesville facility and associated products.
- Non-GAAP net loss was $26.2 million, or
a non-GAAP diluted loss per share of $0.18 for the quarter. This
compared to non-GAAP net income of $3.9 million, or a non-GAAP
diluted earnings per share of $0.03, for the same period in the
prior year, or a non-GAAP net loss of $3.5 million, or a non-GAAP
basic and diluted loss per share of $0.02, excluding $7.4 million
of non-GAAP net income related to the Gainesville facility and
associated products.
Quarter Ended Sept. 30, 2015 Financial
Results
Revenues
- Manufacturing and royalty revenues from
RISPERDAL CONSTA® and INVEGA SUSTENNA®/XEPLION® were $67.6 million,
compared to $68.5 million for the same period in the prior
year.
- Net sales of VIVITROL were $37.9
million, compared to $25.8 million for the same period in the prior
year, representing an increase of approximately 47%.
- Manufacturing and royalty revenues from
AMPYRA®/FAMPYRA®1 were $22.1 million, compared to $16.5 million for
the same period in the prior year.
- Royalty revenue from BYDUREON® was
$13.0 million, compared to $10.3 million for the same period in the
prior year.
Costs and Expenses
- Operating expenses were $230.1 million,
reflecting increased investment in the company’s rapidly advancing
development pipeline and pre-launch activities for ARISTADA, and
included $13.9 million of share-based compensation expense related
to the partial vesting of a performance-based equity grant related
to the approval of ARISTADA. This compared to $192.7 million for
the same period in the prior year, or $180.0 million excluding
$12.7 million of operating expenses related to the Gainesville
facility and associated products.
- Income tax provision was $3.0 million,
compared to $3.5 million for the same period in the prior
year.
Balance Sheet
At Sept. 30, 2015, Alkermes had cash and total investments of
$815.5 million, compared to $801.6 million at Dec. 31, 2014. At
Sept. 30, 2015, the company’s total debt outstanding was $353.2
million.
Conference Call
Alkermes will host a conference call at 8:30 a.m. EDT (12:30
p.m. GMT) on Thursday, Oct. 29, 2015, to discuss these financial
results and provide an update on the company. The conference call
may be accessed by dialing +1 888 424 8151 for U.S. callers and +1
847 585 4422 for international callers. The conference call ID
number is 6037988. In addition, a replay of the conference call
will be available from 11:00 a.m. EDT (3:00 p.m. GMT) on Thursday,
Oct. 29, 2015, through 5:00 p.m. EST (10:00 p.m. GMT) on Thursday,
Nov. 5, 2015, and may be accessed by visiting Alkermes’ website or
by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for
international callers. The replay access code is 6037988.
About Alkermes
Alkermes plc is a fully integrated, global
biopharmaceutical company developing innovative medicines for the
treatment of central nervous system (CNS) diseases. The company has
a diversified commercial product portfolio and a substantial
clinical pipeline of product candidates for chronic diseases that
include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and a manufacturing
facility in Wilmington, Ohio. For more information, please visit
Alkermes’ website at www.alkermes.com.
Non-GAAP Financial
Measures
This press release includes information about certain financial
measures that are not prepared in accordance with generally
accepted accounting principles in the U.S. (GAAP), including
non-GAAP net income or loss, non-GAAP diluted earnings or loss per
share and free cash flow. These non-GAAP measures are not based on
any standardized methodology prescribed by GAAP and are not
necessarily comparable to similar measures presented by other
companies.
Management defines its non-GAAP financial measures as
follows:
- Non-GAAP net income or loss adjusts for
one-time and non-cash charges by excluding from GAAP results:
share-based compensation expense; amortization; depreciation;
non-cash net interest expense; non-cash tax expense; deferred
revenue; and certain other one-time or non-cash items.
- Free cash flow represents non-GAAP net
income or loss less capital expenditures.
The company’s management believes that these non-GAAP financial
measures, when viewed with the company’s results under GAAP and the
accompanying reconciliations, better indicate underlying trends in
ongoing operations and cash flows. However, non-GAAP net income or
loss, non-GAAP diluted earnings or loss per share and free cash
flow are not measures of financial performance under GAAP and,
accordingly, should not be considered as alternatives to GAAP
measures as indicators of operating performance.
A reconciliation of GAAP to non-GAAP financial measures has been
provided in the tables included in this press release.
Note Regarding Forward-Looking
Statements
Certain statements set forth above may constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to: statements concerning future financial and
operating performance, business plans or prospects; the likelihood
of continued revenue growth from the company’s commercial products;
the therapeutic and commercial value of the company’s products; and
expectations concerning the timing and results of development
activities, including the timing of the commencement of the pivotal
programs for ALKS 3831 and ALKS 8700 and the receipt of data from
the first core efficacy study of ALKS 5461. The company cautions
that forward-looking statements are inherently uncertain. Although
the company believes that such statements are based on reasonable
assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor
guarantees and they are necessarily subject to a high degree of
uncertainty and risk. Actual performance and results may differ
materially from those expressed or implied in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include, among others: the impact of litigation,
including litigation against regulatory authorities, in respect of
our products; clinical development activities may not be completed
on time or at all and the results of such activities may not be
predictive of real-world results or of results in subsequent
clinical trials; regulatory submissions may not occur or be
submitted in a timely manner; the company, and its partners, may
not be able to continue to successfully commercialize its products;
there may be a reduction in payment rate or reimbursement for the
company’s products or an increase in the company’s financial
obligations to governmental payers; the U.S. Food and Drug
Administration or regulatory authorities outside the U.S. may make
adverse decisions regarding the company’s products; the company’s
products may prove difficult to manufacture, be precluded from
commercialization by the proprietary rights of third parties, or
have unintended side effects, adverse reactions or incidents of
misuse; and those risks and uncertainties described under the
heading “Item 1A. Risk Factors” in the company’s Annual Report on
Form 10-K for the fiscal year ended Dec. 31, 2014 and under
the heading “Item 1A. Risk Factors” in the company’s Quarterly
Report on Form 10-Q for the fiscal quarter ended Sept. 30,
2015, and in any other subsequent filings made by the company with
the Securities and Exchange Commission (“SEC”), which are available
on the SEC’s website at www.sec.gov. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. The information contained in this press release is
provided by the company as of the date hereof and, except as
required by law, the company disclaims any intention or
responsibility for updating or revising any forward-looking
information contained in this press release.
ARISTADA™ is a trademark of Alkermes Pharma Ireland Limited;
VIVITROL® is a registered trademark of Alkermes, Inc. RISPERDAL
CONSTA®, INVEGA SUSTENNA® and XEPLION® are registered trademarks of
Johnson & Johnson; AMPYRA® and FAMPYRA® are registered
trademarks of Acorda Therapeutics, Inc.; BYDUREON® is a registered
trademark of Amylin Pharmaceuticals, LLC.
1AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is
developed and marketed in the U.S. by Acorda Therapeutics, Inc. and
outside the U.S. by Biogen International GmbH, under a licensing
agreement with Acorda Therapeutics, Inc., as FAMPYRA®
(prolonged-release fampridine tablets).
(tables follow)
Alkermes plc and
SubsidiariesSelected Financial Information (Unaudited)
Three Months Three Months Ended Ended
Condensed
Consolidated Statements of Operations - GAAP September 30,
September 30,
(In thousands, except per share data)
2015 2014 Revenues: Manufacturing and royalty
revenues $ 114,072 $ 132,028 Product sales, net 37,903 25,802
Research and development revenues 678 2,162
Total Revenues 152,653 159,992
Expenses: Cost of goods manufactured and sold 33,806 47,335
Research and development 92,558 78,263 Selling, general and
administrative 89,497 51,888 Amortization of acquired intangible
assets 14,207 15,244 Total Expenses
230,068 192,730 Operating Loss
(77,415 ) (32,738 ) Other Expense, net: Interest income 865
546 Interest expense (3,325 ) (3,356 ) Gain on the Gainesville
Transaction 26 - Increase in the fair value of contingent
consideration 1,200 - Gain on sale of property, plant and equipment
- 36 Other income (expense), net 629 (921 )
Total Other Expense, net (605 ) (3,695 ) Loss Before
Income Taxes (78,020 ) (36,433 ) Income Tax Provision
2,995 3,523
Net Loss — GAAP $
(81,015 ) $ (39,956 )
(Loss) Earnings Per Share: GAAP
loss per share — basic and diluted $ (0.54 ) $ (0.27 ) Non-GAAP
(loss) earnings per share — basic and diluted $ (0.18 ) $ 0.03
Weighted Average Number of Ordinary Shares
Outstanding: Basic and diluted — GAAP 149,512
145,896 Basic — Non-GAAP 149,512
145,896 Diluted — Non-GAAP 149,512
154,399 An itemized reconciliation between net loss
on a GAAP basis and non-GAAP net (loss) income is as follows:
Net Loss — GAAP $ (81,015 ) $ (39,956 ) Adjustments:
Share-based compensation expense 35,267 13,481 Amortization expense
14,207 15,244 Depreciation expense 6,486 9,989 Non-cash taxes 677
3,640 Non-cash net interest expense 234 238 Deferred revenue (725 )
696 Net (gain) loss on transactions with equity method investee
(397 ) 603 Gain on the Gainesville Transaction (26 ) - Increase in
the fair value of contingent consideration (1,200 ) - Change in the
fair value of common stock warrants 318 - Gain on sale of property,
plant and equipment - (36 )
Non-GAAP Net
(Loss) Income $ (26,174 ) $ 3,899 Capital expenditures
11,974 8,888
Free Cash Outflow $
(38,148 ) $ (4,989 ) Nine Months Nine Months
Ended Ended
Condensed Consolidated Statements of Operations -
GAAP September 30, September 30,
(In thousands, except per
share data) 2015 2014 Revenues:
Manufacturing and royalty revenues $ 355,978 $ 373,674 Product
sales, net 106,212 64,476 Research and development revenues
3,047 5,478 Total Revenues 465,237
443,628 Expenses: Cost of goods manufactured
and sold 104,198 129,464 Research and development 250,718 197,610
Selling, general and administrative 224,086 145,101 Amortization of
acquired intangible assets 43,479 42,909
Total Expenses 622,481 515,084
Operating Loss (157,244 ) (71,456 )
Other Income, net: Interest income 2,320 1,380 Interest expense
(9,928 ) (10,097 ) Gain on the Gainesville Transaction 9,937 -
Increase in the fair value of contingent consideration 2,700 - Gain
on sale of investment in Acceleron Pharma Inc. - 15,296 Gain on
sale of property, plant and equipment - 12,321 Other income
(expense), net 1,003 (2,253 ) Total Other
Income, net 6,032 16,647 Loss Before
Income Taxes (151,212 ) (54,809 ) Income Tax
Provision 6,569 5,766
Net Loss —
GAAP $ (157,781 ) $ (60,575 )
(Loss) Earnings Per
Share: GAAP loss per share — basic and diluted $ (1.06 ) $
(0.42 ) Non-GAAP (loss) earnings per share — basic $ (0.21 ) $ 0.26
Non-GAAP (loss) earnings per share — diluted $ (0.21 ) $
0.25
Weighted Average Number of Ordinary Shares
Outstanding: Basic and diluted — GAAP 148,828
144,732 Basic — Non-GAAP 148,828
144,732 Diluted — Non-GAAP 148,828
154,017 An itemized reconciliation between net loss
on a GAAP basis and non-GAAP net (loss) income is as follows:
Net Loss — GAAP $ (157,781 ) $ (60,575 ) Adjustments:
Share-based compensation expense 74,473 46,238 Amortization expense
43,479 42,909 Depreciation expense 20,336 29,810 Non-cash taxes
4,199 5,055 Non-cash net interest expense 705 717 Deferred revenue
(1,627 ) (607 ) Net (gain) loss on transactions with equity method
investee (1,191 ) 1,842 Gain on the Gainesville Transaction (9,937
) - Increase in the fair value of contingent consideration (2,700 )
- Change in the fair value of common stock warrants (558 ) - Gain
on sale of investment in Acceleron Pharma Inc. - (15,296 ) Gain on
sale of property, plant and equipment -
(12,321 )
Non-GAAP Net (Loss) Income $ (30,602 ) $ 37,772
Capital expenditures 36,730 20,326
Free Cash (Outflow) Inflow $ (67,332 ) $ 17,446
Condensed Consolidated Balance Sheets
September 30, December 31,
(In thousands) 2015 2014 Cash,
cash equivalents and total investments $ 815,499 $ 801,646
Receivables 140,987 151,551 Inventory 36,783 51,357 Prepaid
expenses and other current assets 50,893 42,719 Property, plant and
equipment, net 242,675 265,740 Intangible assets, net and goodwill
486,266 573,624 Contingent consideration 60,300 - Other assets
47,552 34,635
Total Assets $
1,880,955 $ 1,921,272 Long-term debt — current
portion $ 66,712 $ 6,750 Other current liabilities 133,690 123,832
Long-term debt 286,512 351,220 Deferred revenue — long-term 7,477
11,801 Other long-term liabilities 19,759 30,832 Total
shareholders' equity 1,366,805 1,396,837
Total Liabilities and Shareholders' Equity $
1,880,955 $ 1,921,272 Ordinary shares
outstanding (in thousands) 149,854 147,539
This selected financial information should be read in
conjunction with the consolidated financial statements and notes
thereto included in Alkermes plc's Quarterly Report on Form 10-Q
for the three and nine months ended September 30, 2015, which the
company intends to file in October 2015.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151029005359/en/
AlkermesFor Investors:Sandy Coombs,
+1-781-609-6377orFor Media:Jennifer Snyder, +1-781-609-6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024